Why innovator pharma companies should be pursuing biosimilars
This article was originally published in SRA
Patent expiries, pricing pressures and the emergence of approval pathways in countries such as China and Brazil mean that biosimilars offer a substantial global opportunity, and there are many good reasons for originator companies to consider investing in this market segment, say Anna Buscall and Christopher Stothers.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."